Cited by 3,394Cancer Genomics and DiagnosticsChromatin Remodeling and CancerGene expression and cancer classification

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Next-generation characterization of the Cancer Cell Line Encyclopedia

Open access

Ghandi, Mahmoud, Huang, Franklin W., Jané-Valbuena, Judit, Kryukov, Gregory V., Lo, Christopher C., McDonald, E. Robert, Barretina, Jordi, Gelfand, Ellen T., Bielski, Craig M., Li, Haoxin, Hu, Kevin, Andreev-Drakhlin, Alexander Y., Kim, Jaegil, Hess, Julian M., Haas, Brian J., Aguet, François, Weir, Barbara A., Rothberg, Michael V., Paolella, Brenton R., Lawrence, Michael S., Akbani, Rehan, Lu, Yiling, Tiv, Hong L., Gokhale, Prafulla C., de Weck, Antoine, Mansour, Ali Amin, Oh, Coyin, Shih, Juliann, Hadi, Kevin, Rosen, Yanay, Bistline, Jonathan, Venkatesan, Kavitha, Reddy, Anupama, Sonkin, Dmitriy, Liu, Manway, Lehar, Joseph, Korn, Joshua M., Porter, Dale A., Jones, Michael D., Golji, Javad, Caponigro, Giordano, Taylor, Jordan E., Dunning, Caitlin M., Creech, Amanda L., Warren, Allison C., McFarland, James M., Zamanighomi, Mahdi, Kauffmann, Audrey, Stransky, Nicolas, Imielinski, Marcin, Maruvka, Yosef E., Cherniack, Andrew D., Tsherniak, Aviad, Vazquez, Francisca, Jaffe, Jacob D., Lane, Andrew A., Weinstock, David M., Johannessen, Cory M., Morrissey, Michael P., Stegmeier, Frank, Schlegel, Robert, Hahn, William C., Getz, Gad, Mills, Gordon B., Boehm, Jesse S., Golub, Todd R., Garraway, Levi A., Sellers, William R.·2019·Nature

DOI 10.1038/s41586-019-1186-3PMC PMC6697103

Open this paper in CoChat — free account

Abstract

Large panels of comprehensively characterized human cancer models, including the Cancer Cell Line Encyclopedia (CCLE), have provided a rigorous framework with which to study genetic variants, candidate targets, and small-molecule and biological therapeutics and to identify new marker-driven cancer dependencies. To improve our understanding of the molecular features that contribute to cancer phenotypes, including drug responses, here we have expanded the characterizations of cancer cell lines to include genetic, RNA splicing, DNA methylation, histone H3 modification, microRNA expression and reverse-phase protein array data for 1,072 cell lines from individuals of various lineages and ethnicities. Integration of these data with functional characterizations such as drug-sensitivity, short hairpin RNA knockdown and CRISPR–Cas9 knockout data reveals potential targets for cancer drugs and associated biomarkers. Together, this dataset and an accompanying public data portal provide a resource for the acceleration of cancer research using model cancer cell lines. The original Cancer Cell Line Encyclopedia (CCLE) is expanded with deeper characterization of over 1,000 cell lines, including genomic, transcriptomic, and proteomic data, and integration with drug-sensitivity and gene-dependency data.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1186-3

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Untitled work
(2008) · Journal of Machine Learning Research · Cited by 33,051
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436
MicroRNA expression profiles classify human cancers
Lü, J., Getz, G. A., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,637
Self-citation
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citation

Show all 67 references

Sorted by citations

Items 501–600 of 1,008

SUCLG1 restricts POLRMT succinylation to enhance mitochondrial biogenesis and leukemia progression
Yan, W., Xie, C., Sun, S., Zheng, Q., Wang, J., Wang, Z., Man, C. H., Wang, H., Yang, Y., Wang, T., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00101-9 · Cited by 41
“Transcriptomes of cancer cell line encyclopedia (Ghandi et al, 2019) revealed that SUCLG1 expression showed a signi ﬁ cantly positive correlation with MRPL45 (Fig.”
DeepDRA: Drug repurposing using multi-omics data integration with autoencoders
Mohammadzadeh-Vardin, T., Ghareyazi, A., Gharizadeh, A., Abbasi, K., & Rabiee, H. R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307649 · Cited by 47
Small-molecule and CRISPR screening converge to reveal RTK dependencies in pediatric rhabdoid tumors
Oberlick, E. M., Rees, M., Seashore-Ludlow, B., Vazquez, F., Nelson, G. M., Dharia, N., Weir, B., Tsherniak, A., Ghandi, M., Krill-Burger, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.021 · Cited by 40
Self-citation
Differential Co-Expression Analyses Allow the Identification of Critical Signalling Pathways Altered during Tumour Transformation and Progression
Savino, A., Provero, P., & Poli, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249461 · Cited by 40
CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance
Harris, K. S., Shi, L., Foster, B. M., Mobley, M. E., Elliott, P. L., Song, C. J., Watabe, K., Langefeld, C. D., & Kerr, B. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-81126-6 · Cited by 43
Data-independent acquisition-based proteome and phosphoproteome profiling across six melanoma cell lines reveals determinants of proteotypes
Gao, E., Li, W., Wu, C., Shao, W., Di, Y., & Liu, Y. (2021) · Molecular Omics · doi:10.1039/d0mo00188k · Cited by 36
Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine
Feng, F., Shen, B., Mou, X., Li, Y., & Li, H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.007 · Cited by 43
Self-citation
From language to action: a review of large language models as autonomous agents and tool users
Chowa, S. S., Alvi, R., Rahman, S. S., Rahman, M. A., Raiaan, M. A. K., Islam, M. R., Hussain, M., & Azam, S. (2026) · Artificial Intelligence Review · doi:10.1007/s10462-025-11471-9 · Cited by 50
Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification
Saatci, Ö., Akbulut, Ö., Çetįn, M., Sikirzhytski, V., Üner, M., Lengerli, D., O’Quinn, E. C., Romeo, M. J., Çalışkan, B., Banoğlu, E., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01140-1 · Cited by 42
“The Cancer Genome Atlas (TCGA) [56] patient data (prostate cancer) and the CCLE data [57] were downloaded using the cBIO dataset [58].”
Method
The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer
Kampa, M., Notas, G., Stathopoulos, E. N., Tsapis, A., & Castanas, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00827 · Cited by 43
Allele‐specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers
Rowland, T. J., Bonham, A. J., & Cech, T. R. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12786 · Cited by 41
TOP2A and CENPF are synergistic master regulators activated in cervical cancer
Yu, B., Chen, L., Zhang, W., Li, Y., Zhang, Y., Gao, Y., Teng, X., Zou, L., Wang, Q., Jia, H., et al. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00800-2 · Cited by 40
Urea as a By-Product of Ammonia Metabolism Can Be a Potential Serum Biomarker of Hepatocellular Carcinoma
Bai, C., Wang, H., Dong, D., Li, T., Yu, Z. H., Guo, J., Zhou, W., Ding, L., Yan, R., Wang, L., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650748 · Cited by 39
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fan, F., Malvestiti, S., Vallet, S., Lind, J., García-Manteiga, J. M., Morelli, E., Jiang, Q., Seckinger, A., Hose, D., Goldschmidt, H., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01271-9 · Cited by 40
RETRACTED: Multiple strategies with the synergistic approach for addressing colorectal cancer
Karthika, C., Hari, B., Rahman, M. H., Akter, R., Najda, A., Albadrani, G. M., Sayed, A. A., Akhtar, M. F., & Abdel‐Daim, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111704 · Cited by 41
Retracted
A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models
Zhong, Z., Harmston, N., Wood, K. C., Madan, B., & Virshup, D. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156305 · Cited by 39
“Patu8988T WGS data from SRX5466648 (23) were visualized using the Integrative Genomics Viewer (IGV).”
BackgroundMethodInfluential
Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y. G., Teicher, B. A., & Krushkal, J. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01026-4 · Cited by 41
Induction of Viral Mimicry Upon Loss of DHX9 and ADAR1 in Breast Cancer Cells
Cottrell, K. A., Ryu, S., Pierce, J. R., Torres, L. S., Bohlin, H. E., Schab, A. M., & Weber, J. D. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0488 · Cited by 39
The road towards data integration in human genomics: players, steps and interactions
Bernasconi, A., Canakoglu, A., Masseroli, M., & Ceri, S. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa080 · Cited by 39
Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models
Coulson‐Gilmer, C., Morgan, R. D., Nelson, L., Barnes, B. M., Tighe, A., Wardenaar, R., Spierings, D. C. J., Schlecht, H., Burghel, G. J., Foijer, F., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02124-0 · Cited by 38
Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis
Duan, S., Moro, L., Qu, R., Simoneschi, D., Cho, H., Jiang, S., Zhao, H., Chang, Q., de Stanchina, E., Arbini, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109870 · Cited by 40
Onco-miR-21 Promotes Stat3-Dependent Gastric Cancer Progression
Tse, J. W. T., Pierce, T. P., Carli, A. L. E., Alorro, M., Thiem, S., Marcusson, E. G., Ernst, M., & Büchert, M. (2022) · Cancers · doi:10.3390/cancers14020264 · Cited by 40
“Proteomics data miRNA expression data for the gastric cancer cell line were obtained from the CCLE platform [47,48].”
Method
Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy
Zhang, Z., & Wei, X. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.005 · Cited by 41
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer
Das, R., Sjöström, M., Shrestha, R., Yogodzinski, C., Egusa, E. A., Chesner, L. N., Chen, W. S., Chou, J., Dang, D. K., Swinderman, J. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24919-7 · Cited by 38
Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap
Shi, B., Ding, J., Qi, J., & Gu, Z. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51703 · Cited by 39
Widespread genetic heterogeneity of human ribosomal RNA genes
Fan, W., Eklund, E., Sherman, R. M., Liu, H., Pitts, S. C., Ford, B. L., Rajeshkumar, N. V., & Laiho, M. (2022) · RNA · doi:10.1261/rna.078925.121 · Cited by 38
“The CCLEWGS data set was generated using PCR amplification (Ghandi et al. 2019).”
Method
Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein–Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases
Li, F., Aljahdali, I. A. M., & Ling, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116206 · Cited by 38
Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells
Gauthier-Coles, G., Bröer, A., McLeod, M. D., George, A. J., Hannan, R. D., & Bröer, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.963066 · Cited by 38
“All cell lines express high levels of SNAT2 mRNA (log (2)transformed RNAseq counts from the Cancer Cell Line Encyclopedia (Ghandi et al., 2019): HPAFII 7.47, HCC 1806, 6.35, MDA-MB-231 6.54, OVCAR3 7.33, SKOV36.”
Influential
A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer
Baptista, D., Ferreira, P. G., & Rocha, M. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010200 · Cited by 39
“RNA-Seq (TPM) CCLE [26] (DepMap) https://depmap.”
MethodInfluential
Lipid droplets are a metabolic vulnerability in melanoma
Lumaquin, D., Montal, E. D., Johns, E., Baggiolini, A., Huang, T. H., Ma, Y., LaPlante, C., Suresh, S., Studer, L., & White, R. M. (2023) · Nature Communications · doi:10.1038/s41467-023-38831-9 · Cited by 46
“Log 2 normalized counts fromCCLE and TCGA melanoma datasets were retrieved from publicly available databases: https://depmap.org/ portal/download/all/ and https://tcga.xenahubs.net.”
Influential
Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer
Dong, X., Liao, P., Liu, X., Yang, Z., Wang, Y., Zhong, W., & Wang, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612915 · Cited by 39
“The cell line LncRNA expression matrix of COAD was obtained from the CCLE dataset (https://portals.broadinstitute.org/ccle (accessed on 15 May 2023)) [69].”
Integration of 3D bioprinting and multi-algorithm machine learning identified glioma susceptibilities and microenvironment characteristics
Tang, M., Jiang, S., Huang, X., Ji, C., Gu, Y., Qi, Y., Xiang, Y., Yao, E. J., Zhang, N., Berman, E. L., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00650-7 · Cited by 38
Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions
Hiatt, J. B., Doebley, A.-L., Arnold, H. U., Adil, M., Sandborg, H., Persse, T. W., Ko, M., Wu, F., Quintanal-Villalonga, À., Santana-Dávila, R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk2082 · Cited by 40
“REST is not only most commonly active in POU2F3-positive SCLC but can also be active in other SCLC subtypes and is highly active in LUAD and LUSC NSCLC ( 41 ).”
BackgroundMethodInfluential
Building a translational cancer dependency map for The Cancer Genome Atlas
Shi, X., Gekas, C., Verduzco, D., Petiwala, S. M., Jeffries, C. T., Lu, C., Murphy, E., Anton, T., Vo, A. H., Xiao, Z., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00789-y · Cited by 39
Poor clinical outcome in metastatic melanoma is associated with a microRNA-modulated immunosuppressive tumor microenvironment
Jorge, N. A. N., da Cruz, J. G. V., Pretti, M. A. M., Bonamino, M., Possik, P. A., & Boroni, M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02235-w · Cited by 38
Mdm2: Open questions
Dobbelstein, M., & Levine, A. J. (2020) · Cancer Science · doi:10.1111/cas.14433 · Cited by 40
Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma
Ohguchi, H., Park, P. M. C., Wang, T., Gryder, B. E., Ogiya, D., Kurata, K., Zhang, X., Li, D., Pei, C., Masuda, T., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0108 · Cited by 38
Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
Chen, N., Xu, Y., Mou, J., Rao, Q., Xing, H., Tian, Z., Tang, K., Wang, M., & Wang, J. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00536-x · Cited by 39
RBM6 splicing factor promotes homologous recombination repair of double-strand breaks and modulates sensitivity to chemotherapeutic drugs
Machour, F. E., Abu‐Zhayia, E. R., Awwad, S. W., Bidany-Mizrahi, T., Meinke, S., Bishara, L. A., Heyd, F., Aqeilan, R. I., & Ayoub, N. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab976 · Cited by 38
Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach
Li, X., Shong, K. E., Kim, W., Yuan, M., Yang, H., Sato, Y., Kume, H., Ogawa, S., Türkez, H., Shoaie, S., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103963 · Cited by 38
Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions
Koşaloğlu‐Yalçın, Z., Lee, J., Greenbaum, J., Schoenberger, S. P., Miller, A. M., Kim, Y. J., Sette, A., Nielsen, M., & Peters, B. (2022) · iScience · doi:10.1016/j.isci.2022.103850 · Cited by 37
“Line Encyclopedia (Ghandi et al., 2019) CCLE_RNAseq_rsem_genes_tpm_20180929.txt.gz https://depmap.org/portal/download/api/download? file_name=ccle%2Fccle_2019%2FCCLE_RNAseq_rsem_ genes_tpm_20180929.txt.gz&bucket=depmap-externaldownloads”
Influential
An oncogenic enhancer encodes selective selenium dependency in AML
Eagle, K., Jiang, Y., Shi, X. E., Li, M., Obholzer, N. D., Hu, T., Perez, M. W., Koren, J. V., Kitano, A., Yi, J. S., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.01.003 · Cited by 40
High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities
Roh, W., Geffen, Y., Cha, H., Miller, M. L., Anand, S. K., Kim, J., Heiman, D. I., Gainor, J. F., Laird, P. W., Cherniack, A. D., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0432 · Cited by 37
Self-citation
Systematic discovery and functional dissection of enhancers needed for cancer cell fitness and proliferation
Chen, P. B., Fiaux, P. C., Zhang, K., Li, B., Kubo, N., Jiang, S., Hu, R., Rooholfada, E., Wu, S., Wang, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111630 · Cited by 41
“In addition, a recent large-scale CRISPR-Cas9-based loss-of-function screens further uncovered ~2,000 genes essential for proliferation in diverse cancer cell lines (Ghandi et al., 2019).”
Influential
UTRdb 2.0: a comprehensive, expert curated catalog of eukaryotic mRNAs untranslated regions
Giudice, C. L., Zambelli, F., Chiara, M., Pavesi, G., Tangaro, M. A., Picardi, E., & Pesole, G. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1016 · Cited by 36
Clinically relevant fusion oncogenes: detection and practical implications
Sorokin, M., Rabushko, E., Rozenberg, J. M., Mohammad, T., Seryakov, A., Sekacheva, M. I., & Buzdin, A. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221144108 · Cited by 39
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas
Liu, S., Chai, T., Garcia-Marques, F. J., Yin, Q., Hsu, E., Shen, M., Toland, A. M. S., Bermudez, A., Hartono, A. B., Massey, C. F., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101381 · Cited by 37
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling
Würth, R., Donato, E., Michel, L. L., Saini, M., Becker, L., Cheytan, T., Doncevic, D., Meßmer, T., Gutjahr, E., Weber, R., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00882-2 · Cited by 37
Synergy between Non-Thermal Plasma with Radiation Therapy and Olaparib in a Panel of Breast Cancer Cell Lines
Lafontaine, J., Boisvert, J.-S., Glory, A., Coulombe, S., & Wong, P. (2020) · Cancers · doi:10.3390/cancers12020348 · Cited by 37
A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discovery
Creason, A., Haan, D., Dang, K., Chiotti, K., Inkman, M. J., Lamb, A. E., Yu, T. V., Hu, Y., Norman, T., Buchanan, A., et al. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.021 · Cited by 37
Self-citation
Argonaute binding within human nuclear RNA and its impact on alternative splicing
Chu, Y., Yokota, S., Liu, J., Kilikevičius, A., Johnson, K. C., & Corey, D. R. (2021) · RNA · doi:10.1261/rna.078707.121 · Cited by 35
Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma
Li, Y., Xu, F., Chen, F., Chen, Y., Ge, D., Zhang, S., & Lu, C. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103510 · Cited by 38
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105505 · Cited by 37
The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer
Liu, W., Newhall, K. P., Khani, F., Barlow, L. J., Nguyen, D., Gu, L. C., Eng, K. W., Bhinder, B., Uppal, M., Récapet, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2912 · Cited by 39
Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Sahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Qian, G., Nicol, P., Zeng, Z., Wang, C., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0244 · Cited by 35
“Future clinical investigations are required to reveal whether immunotherapy-resistant tumors benefit from the immunostimulatory effect of ESRRA inhibition”
Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities
Zhang, Y., Remillard, D., Onubogu, U., Karakyriakou, B., Asiaban, J. N., Ramos, A. R., Bowland, K., Bishop, T. R., Barta, P. A., Nance, S., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01041-4 · Cited by 35
Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
Novoplansky, O., Shnerb, A. B., Marripati, D., Jagadeeshan, S., Shareb, R. A., Conde‐López, C., Zorea, J., Prasad, M., Lulu, T. B., Yegodayev, K. M., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13500 · Cited by 37
TEQUILA-seq: a versatile and low-cost method for targeted long-read RNA sequencing
Wang, F., Xu, Y., Wang, R., Zhang, B. D., Smith, N., Notaro, A., Gaerlan, S., Kutschera, E., Kadash-Edmondson, K. E., Xing, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40083-6 · Cited by 38
“All WGS reads covering this region contain the same mutation, as the other allele of TP53 is lost in the tumor genome of HCC1599 through loss of heterozygosity 48 .”
Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer
Wang, S., Wu, C., He, M.-M., Yong, J.-X., Chen, Y., Qian, L.-M., Zhang, J., Zeng, Z.-L., Xu, R., Wang, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45479-6 · Cited by 36
Convergence of CRISPR and artificial intelligence: A paradigm shift in biotechnology
Dara, M., Dianatpour, M., Azarpira, N., & Omidifar, N. (2024) · Human Gene · doi:10.1016/j.humgen.2024.201297 · Cited by 36
Role of Lipopolysaccharides in the Inflammation and Pyroptosis of Alveolar Epithelial Cells in Acute Lung Injury and Acute Respiratory Distress Syndrome
Shen, X. L., He, L., & Cai, W. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s479051 · Cited by 36
Diminished Condensin Gene Expression Drives Chromosome Instability That May Contribute to Colorectal Cancer Pathogenesis
Baergen, A. K., Jeusset, L. M., Lichtensztejn, Z., & McManus, K. J. (2019) · Cancers · doi:10.3390/cancers11081066 · Cited by 36
The Circular RNA Landscape of Non-Small Cell Lung Cancer Cells
Steen, N. V. D., Lyu, Y., Hitzler, A. K., Becker, A. C., Seiler, J., & Diederichs, S. (2020) · Cancers · doi:10.3390/cancers12051091 · Cited by 37
Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
Chong, W., Wang, Z., Shang, L., Jia, S., Liu, J., Fang, Z., Du, F., Wu, H., Liu, Y., Chen, Y., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.033 · Cited by 37
Auto-HMM-LMF: feature selection based method for prediction of drug response via autoencoder and hidden Markov model
Emdadi, A., & Eslahchi, C. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-03974-3 · Cited by 36
A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders
Fischer, P. D., Papadopoulos, E., Dempersmier, J. M., Wang, Z., Nowak, R. P., Donovan, K. A., Kalabathula, J., Gorgulla, C., Junghanns, P., Kabha, E., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113435 · Cited by 37
Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
Błaszczak, W., Liu, G., Zhu, H., Barczak, W., Shrestha, A., Albayrak, G., Zheng, S., Kerr, D. J., Samsonova, A. A., & Thangue, N. B. L. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12953 · Cited by 37
Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Zañudo, J. G. T., Mao, P., Alcon, C., Kowalski, K. J., Johnson, G. N., Xu, G., Baselga, J. M., Scaltriti, M., Letai, A. G., Montero, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1208 · Cited by 37
The Evolving Genomic Landscape of Esophageal Squamous Cell Carcinoma Under Chemoradiotherapy
Hirata, H., Niida, A., Kakiuchi, N., Uchi, R., Sugimachi, K., Masuda, T., Saito, T., Kageyama, S., Motomura, Y., Ito, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0653 · Cited by 37
RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics
Bekele, R. T., Samant, A. S., Nassar, A. H., So, J., Garcia, E. P., Curran, C. R., Hwang, J. H., Mayhew, D. L., Nag, A., Thorner, A. R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147849 · Cited by 39
CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma
Cai, C., Zhang, Y., Hu, X., Hu, W., Yang, S., Qiu, H., & Chu, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.721644 · Cited by 37
Cancer catecholamine conundrum
Wackerhage, H., Christensen, J. F., Ilmer, M., von Luettichau, I., Renz, B. W., & Schönfelder, M. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.005 · Cited by 36
Comparative optimization of combinatorial CRISPR screens
Li, R., Klingbeil, O., Monducci, D., Young, M. J., Rodriguez, D. J., Bayyat, Z., Dempster, J. M., Kesar, D., Yang, X., Zamanighomi, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30196-9 · Cited by 37
Self-citation
Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
Lee, P. C., Klaeger, S., Le, P. M., Korthauer, K. D., Cheng, J., Ananthapadmanabhan, V., Frost, T. C., Stevens, J. D., Wong, A. Y. L., Iorgulescu, J. B., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci151666 · Cited by 38
“(H) Unsupervised clustering by Euclidian distance of RNA-Seq expression values of class I pathway genes and MYC family genes across all cancer cell lines in the Cancer Cell Line Encyclopedia (44).”
Influential
Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer
Achreja, A., Yu, T., Mittal, A., Choppara, S., Animasahun, O. H., Nenwani, M., Wuchu, F., Meurs, N., Mohan, A., Jeon, J. H., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00636-3 · Cited by 33
AKT3 expression in mesenchymal colorectal cancer cells drives growth and is associated with epithelial-mesenchymal transition
Buikhuisen, J. Y., Gomez Barila, P. M., Torang, A., Dekker, D., de Jong, J. H., Cameron, K., Vitale, S., Stassi, G., van Hooff, S. R., Castro, M. A. A., et al. (2021) · Cancers · doi:10.3390/cancers13040801 · Cited by 33
AIME: Autoencoder-based integrative multi-omics data embedding that allows for confounder adjustments
Yu, T. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009826 · Cited by 34
“The CCLE is a collection of ~1000 cancer cell lines, on which multiple omics measurements were made in order to elucidate the mechanisms of different cancers [28].”
Background
EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer
Kang, J., Chun, J., Hwang, J. S., Pan, C., Li, J., Boese, A. C., Young, I., Malin, C. M., Kang, Y., Gibbons, D. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111827 · Cited by 35
Gene Expression Profiles in Cancers and Their Therapeutic Implications
Creighton, C. J. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000638 · Cited by 35
Nicotinamide N‐methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer
Couto, J., Vulin, M., Jehanno, C., Coissieux, M.-M., Hamelin, B., Schmidt, A., Ivanek, R., Sethi, A., Bräutigam, K., Frei, A., et al. (2023) · EMBO Journal · doi:10.15252/embj.2022112559 · Cited by 31
“In addition, we found that the abundance of 1-MNA (the end product of the NNMT-catalyzed reaction) was generally low in luminal compared to basal-like breast cancer cell lines (Fig EV1E; Sarri (cid:2) o et al , 2008; Ghandi et al , 2019).”
Molecular Characterization and Landscape of Breast cancer Models from a multi-omics Perspective
Ortiz, M. M. O., & Andrechek, E. R. (2023) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-023-09540-2 · Cited by 35
The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities
Ramberger, E., Sapozhnikova, V., Ng, Y. L. D., Dolnik, A., Ziehm, M., Popp, O., Sträng, E., Kull, M., Grünschläger, F., Krüger, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00784-3 · Cited by 47
“2f) 28,29 .”
Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM
Luan, F., Cui, Y., Huang, R., Yang, Z., & Qiao, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-85444-x · Cited by 37
The S-phase-induced lncRNA SUNO1 promotes cell proliferation by controlling YAP1/Hippo signaling pathway
Hao, Q., Zong, X., Sun, Q., Lin, Y.-C., Song, Y. J., Hashemikhabir, S., Hsu, R. Y. C., Kamran, M. Z., Chaudhary, R., Tripathi, V., et al. (2020) · eLife · doi:10.7554/elife.55102 · Cited by 35
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
Vitiello, P. P., Martini, G., Mele, L. L., Giunta, E. F., Falco, V. D., Ciardiello, D., Belli, V., Cardone, C., Matrone, N., Poliero, L., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01811-8 · Cited by 35
Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer
Burston, H. E., Kent, O. A., Communal, L., Udaskin, M. L., Sun, R., Brown, K. R., Jung, E., Francis, K. E., Rose, J. L., Lowitz, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142677 · Cited by 35
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
Hsu, E., Shen, M., Aslan, M., Liu, S., Kumar, M., Garcia-Marques, F. J., Nguyen, H. M., Nolley, R., Pitteri, S. J., Corey, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92552-x · Cited by 35
The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells
Naro, C., Musso, M. D., Monache, F. D., Panzeri, V., de la Grange, P., & Sette, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02210-3 · Cited by 35
Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening
Zeng, Z. R., Zhang, X., Jiang, C., Zhang, Y., Wu, X., Li, J., Tang, S., Li, L., Gu, L., Xie, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02177-1 · Cited by 35
Precision Combination Therapies Based on Recurrent Oncogenic Coalterations
Li, X., Kong, E., Yan, G., Dereli, Z., Bozorgui, B., Imanirad, P., Elnaggar, J. H., Luna, A., Menter, D. G., Pilie, P. G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0832 · Cited by 34
A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses
Gross, S. M., Dane, M. A., Smith, R. L., Devlin, K. L., McLean, I. C., Derrick, D. S., Mills, C. E., Subramanian, K., London, A. B., Torre, D., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03975-9 · Cited by 29
Self-citation
WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia
Hu, J., Wang, T., Xu, J., Wu, S., Wang, L., Su, H., Jiang, J., Yue, M., Wang, J., Wang, D., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.231126 · Cited by 34
Identifying the genes impacted by cell proliferation in proteomics and transcriptomics studies
Locard‐Paulet, M., Palasca, O., & Jensen, L. J. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010604 · Cited by 34
“) [13], normalized gene expression levels in TPM (transcripts per million) units were obtained from the DepMap portal (depmap.”
Method
Computational drug repurposing by exploiting large-scale gene expression data: Strategy, methods and applications
He, H., Duo, H., Hao, Y., Zhang, X., Zhou, X., Zeng, Y., Li, Y., & Li, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106671 · Cited by 35
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Keller, P. J., Adams, E. J., Wu, R., Côté, A., Arora, S., Cantone, N. R., Meyer, R., Mertz, J. A., Gehling, V. S., Cui, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0398 · Cited by 35
“Using CCLE-derived expression data for these lines (43), it was found that the PC1-positive genes were more highly expressed at baseline in insensitive cell lines ( Fig.”
Method
A consensus platform for antibody characterization
Ayoubi, R., Ryan, J., Bolívar, S. G., Alende, C., Moleón, V. R., Fotouhi, M., Alqazzaz, M., Southern, K., Alshafie, W., Baker, M. R., et al. (2024) · Nature Protocols · doi:10.1038/s41596-024-01095-8 · Cited by 35
“Assessment of target expression in each cell line is conducted using RNA sequencing data accessible via the Cancer Dependency Map Portal (DepMap (https://depmap.org); RRID: SCR_017655), which offers transcriptomic profiles for over a thousand cancer cell lines 35 .”
Computational frameworks transform antagonism to synergy in optimizing combination therapies
Chen, J., Lin, A., Jiang, A., Qi, C., Liu, Z., Cheng, Q., Yuan, S., & Luo, P. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01435-2 · Cited by 38
“Drawing from DrugComb 39 , Chemical Database, and Enzymes of the BioMolecular General Repository Laboratory 40 , HuRI 41 , and Cancer Cell Line Encyclopedia 42 , DGSSynADR leverages comprehensive drug interaction data and multi-omics information to power its predictions 38 .”
Holding on to Junk Bonds: Intron Retention in Cancer and Therapy
Monteuuis, G., Schmitz, U., Petrova, V., Kearney, P. S., & Rasko, J. E. J. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1943 · Cited by 34
A Detailed Catalogue of Multi-Omics Methodologies for Identification of Putative Biomarkers and Causal Molecular Networks in Translational Cancer Research
Vlachavas, E., Bohn, J. R., Ückert, F., & Nürnberg, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062822 · Cited by 37
Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation
Pyko, J., Rosemann, J., Müller, L., Kappler, M., Eckert, A. W., Glaß, M., Misiak, D., Hüttelmaier, S., Ballhausen, W. G., Hatzfeld, M., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01384-w · Cited by 34

Authors: Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., Hu, K., Andreev-Drakhlin, A. Y., Kim, J., Hess, J. M., Haas, B. J., Aguet, F., Weir, B. A., Rothberg, M. V., Paolella, B. R., Lawrence, M. S., Akbani, R., Lu, Y., Tiv, H. L., Gokhale, P. C., de Weck, A., Mansour, A. A., Oh, C., Shih, J., Hadi, K., Rosen, Y., Bistline, J., Venkatesan, K., Reddy, A., Sonkin, D., Liu, M., Lehar, J., Korn, J. M., Porter, D. A., Jones, M. D., Golji, J., Caponigro, G., Taylor, J. E., Dunning, C. M., Creech, A. L., Warren, A. C., McFarland, J. M., Zamanighomi, M., Kauffmann, A., Stransky, N., Imielinski, M., Maruvka, Y. E., Cherniack, A. D., Tsherniak, A., Vazquez, F., Jaffe, J. D., Lane, A. A., Weinstock, D. M., Johannessen, C. M., Morrissey, M. P., Stegmeier, F., Schlegel, R., Hahn, W. C., Getz, G., Mills, G. B., Boehm, J. S., Golub, T. R., Garraway, L. A., & Sellers, W. R.
Affiliations: Broad Institute (US)
The University of Texas MD Anderson Cancer Center (US)
Cornell University (US)
National Cancer Institute (US)
Novartis Institutes for BioMedical Research (CH)
Dana-Farber Cancer Institute (US)
Corresponding author: Sellers, William R.
ORCID: Ghandi, Mahmoud
Huang, Franklin W.
Kryukov, Gregory V.
McDonald, E. Robert
Barretina, Jordi
Li, Haoxin
Hu, Kevin
Andreev-Drakhlin, Alexander Y.
Kim, Jaegil
Hess, Julian M.
Haas, Brian J.
Aguet, François
Rothberg, Michael V.
Paolella, Brenton R.
Lawrence, Michael S.
Akbani, Rehan
Lu, Yiling
Tiv, Hong L.
Gokhale, Prafulla C.
Oh, Coyin
Shih, Juliann
Hadi, Kevin
Rosen, Yanay
Venkatesan, Kavitha
Reddy, Anupama
Sonkin, Dmitriy
Liu, Manway
Korn, Joshua M.
Jones, Michael D.
Taylor, Jordan E.
Creech, Amanda L.
McFarland, James M.
Zamanighomi, Mahdi
Kauffmann, Audrey
Stransky, Nicolas
Imielinski, Marcin
Maruvka, Yosef E.
Cherniack, Andrew D.
Tsherniak, Aviad
Jaffe, Jacob D.
Lane, Andrew A.
Weinstock, David M.
Johannessen, Cory M.
Stegmeier, Frank
Hahn, William C.
Getz, Gad
Mills, Gordon B.
Boehm, Jesse S.
Golub, Todd R.
Garraway, Levi A.
Sellers, William R.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-05
Volume: 569
Issue: 7757
Pages: 503-508
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1186-3
PMC: PMC6697103
OpenAlex: W2944727022
Semantic Scholar: b3631d8d2656c0c72ad92f3b0a77af2afde649a5
Cited by: 3,394
References: 67
Citations by year: 2026: 297 · 2025: 472 · 2024: 560 · 2023: 551 · 2022: 550 · 2021: 594 · 2020: 306 · 2019: 59
FWCI: 121.99
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: European Hematology Association (TRTH56)
National Institutes of Health (5r21da025720-02)
National Institute on Drug Abuse (R21-DA025720)
National Cancer Institute (R50CA221675, P50CA217685, R01CA219943, P50CA098258, U24CA180922, U54CA224068, U24CA210949, U24CA210950, R50CA211461, R37CA225191, U01CA217842, U01CA176058, P30CA016672)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
Keywords: Cancer Cell Line Encyclopedia, cancer cell lines, drug sensitivity, gene dependency, RNA splicing, DNA methylation, histone H3 modifications, microRNA expression, reverse phase protein array, CRISPR/Cas9 knockout, shRNA knockdown, therapeutic target, biomarkers, multi-omics integration, public data portals
MeSH terms: Gene Editing, Antineoplastic Agents, Ethnicity, Histones, Humans, Neoplasms, RNA Splicing, Biomarkers, Tumor, Drug Resistance, Neoplasm, DNA Methylation, MicroRNAs, Protein Array Analysis, Cell Line, Tumor, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Next-generation characterization of the Cancer Cell Line Encyclopedia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks